Cholangiocarcinoma clinical trials focus on newly discovered treatments, allowing participants to start benefiting from those treatments as quickly as possible while researchers compare their effectiveness to the current standard of care. If one of these important research studies shows that a new treatment is more effective, or equally effective but associated with fewer side effects, than the currently available options, the new treatment may become the standard of care for bile duct cancer. In this way, cholangiocarcinoma clinical trials can advance treatment options – and provide a source of hope – for all current and future patients who are diagnosed with this relatively rare form of cancer.
Through cholangiocarcinoma clinical trials, patients have opportunities to access promising new therapies, such as:
- New surgical techniques
- New chemotherapy drugs and drug combinations
- Anti-angiogenesis therapies
- Epidermal growth factor receptor (EGFR) inhibitors
- Photodynamic therapy (PDT)
- Molecular therapy
- Hyperthermia therapy
- Gene profiling
Moffitt Cancer Center offers a robust portfolio of cholangiocarcinoma clinical trials, and as a National Cancer Institute-designated Comprehensive Cancer Center, our extensive research efforts and breakthroughs are widely respected. Individuals who are interested in participating in our clinical trials can consult with our multispecialty team of bile cancer experts with or without referrals. We develop highly individualized treatment plans, which may include clinical trial recommendations. At Moffitt, the health and safety of our patients is our top priority, and we monitor each patient’s progress on an ongoing basis, making treatment adjustments as necessary to ensure the best possible outcome and quality of life.
If you are interested in cholangiocarcinoma clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.